AllianceBernstein’s Humacyte HUMA Stock Holding History

AllianceBernstein’s Portfolio HUMA Stock Details HUMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-145,560	Closed	-$140K	–	3374
2026 Q1	$140K	Hold	145,560	–	–	﹤0.01%	3127
2025 Q4	$140K	Hold	145,560	–	–	﹤0.01%	3134
2025 Q3	$253K	Hold	145,560	–	–	﹤0.01%	3001
2025 Q2	$304K	Buy	145,560 +79,970	+122%	+$154K	﹤0.01%	2904
2025 Q1	$112K	Hold	65,590	–	–	﹤0.01%	3053
2024 Q4	$331K	Hold	65,590	–	–	﹤0.01%	2820
2024 Q3	$357K	Sell	65,590 -29,720	-31%	-$196K	﹤0.01%	2831
2024 Q2	$457K	Buy	95,310 +49,980	+110%	+$260K	﹤0.01%	2718
2024 Q1	$141K	Hold	45,330	–	–	﹤0.01%	2989
2023 Q4	$129K	Hold	45,330	–	–	﹤0.01%	3034
2023 Q3	$133K	Buy	45,330 +8,000	+21%	+$26.5K	﹤0.01%	3026
2023 Q2	$107K	Buy	37,330 +19,430	+109%	+$70K	﹤0.01%	3073
2023 Q1	$55.3K	Buy	17,900 +2,400	+15%	+$6.82K	﹤0.01%	3087
2022 Q4	$32.7K	Buy	+15,500	New	+$47.1K	﹤0.01%	3196

Other funds holding HUMA

Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

AllianceBernstein's HUMA Position: Q2 2026 in Review

AllianceBernstein sold out of Humacyte (HUMA) in Q2 2026, closing a stake of 145,560 shares — an estimated $140K sold.

AllianceBernstein first reported a position in HUMA in Q4 2022 and held it in 14 quarters. The position peaked at $457K in Q2 2024. 161 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

AllianceBernstein reported no remaining Humacyte position as of Q2 2026 after selling out during the quarter.
AllianceBernstein sold 145,560 Humacyte shares in Q2 2026, an estimated $140K.
AllianceBernstein first reported a position in Humacyte in Q4 2022 and held it in 14 quarters.
AllianceBernstein's Humacyte position peaked at $457K in Q2 2024.
161 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.